The Outlook for the Cardiovascular Disorders Market Remains Robust According to New Report

   The cardiovascular therapeutic area has historically provided the largest single source of revenue for the pharmaceutical industry. The outlook for the market remains robust, driven by high patient populations and a widespread focus on preventative treatment. However, low growth rates in established indications will prevail due to the growing availability of effective generic medicines and an overall scarcity of innovative new drug launches.

   With product launches in mainstream cardiovascular indications facing continued difficulties, major pharma companies are now primarily focusing efforts upon compliance and protection against the generic threats posed by line extensions and combination treatments. Changes in the competitive positions of leading companies will become inevitable as new revenue sources continue to decline and established portfolios under perform.

   The Cardiovascular Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across all major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the period 2007-12.

   With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth. Discover the key market trends and growth drivers of the cardiovascular market, assess the competitive dynamics of leading companies and evaluate the future prospects of major products with this new report...

   Some key findings from this report...

   -Zetia, Diovan, Crestor and Lipitor were the strongest performing major products of 2006-07. Each of these brands is forecast to maintain patent protection over the short to medium-term.

   -The cardiovascular portfolios of Novartis and AstraZeneca are best positioned for high levels of future growth. Conversely, it is forecast that current market leaders Pfizer,Merck and Sanofi-Aventis will struggle to preserve their market shares over the 2008-12 period.

   -The cardiac therapy area is the only segment forecast to experience a decline in net sales during the forecast period. However, generic competition to Lipitor may also result in the Dyslipidemia market suffering a fall in sales over 2011-12.

   -Thrombosis will be the major growth driver of the cardiovascular area throughout the short-term, whilst heart failure has the most favourable dynamics of any indication for rapid market growth.

   -Heart failure and thrombosis represent the most active areas of current drug development. Increasing competition in these traditionally less competitive therapeutic areas is forecast to become a major trend over the period up to 2012.

   Top five reasons to order your copy today

   -Assess patient potential, treatment trends and sales patterns across major cardiovascular indications with this report's analysis of epidemiological studies, unmet medical need, and economic imperatives for stakeholders.

   -Measure the market performance and strategic positioning of major pharmaceutical corporations with this report's evaluation of the franchises and market shares of AstraZeneca, BMS, Daiichi Sankyo, GSK, Merck, Novartis, Pfizer, Sanofi-Aventis and Servier.

   -Discover the market dynamics of the cardiovascular area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.

   -Compare the future prospects of key players and forecast sales of leading products across major indications to 2012 with this report's analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and trends in promotional spend for key brands.

   -Identify the strategies that offer the greatest success potential within the future cardiovascular market and understand the challenges currently facing companies within this therapeutic area.

   Key issues examined in this report...

   -Cardiac therapies. Heart failure treatments have become a focal point for cardiovascular drug developments. However, doubts remain over whether the marginal benefits offered by such medicines will be sufficient to generate and sustain high levels of revenue.

   -Combination drugs. Although combination drugs failed to accrue strong sales growth in 2007, the growing acceptance of combination dyslipidemic therapies amongst payors and physicians will favour Merck's Vytorin/Inegy and Novartis' newly launched combination product Exforge (amlodipine/losartan)

   -Empty pipelines. Currently marketed portfolios have taken on greater importance in light of weak late stage pipelines among players such as Merck, BMS and AstraZeneca. This lack of new revenue sources is forecast to depress future growth in the cardiovascular market.

   -Market leaders. Few leading companies are expected to retain their presence in the cardiovascular market, with some major players set to experience drastic declines in revenue over the forecast period.

   Keywords: Research and Markets, Thrombosis, Cardiology, Cardiovascular, Dyslipidemias, Patents Actions, Biotechnology, Drug Development, Therapy, Treatment, Sanofi-Aventis, Pharmaceutical Business, Pharmaceutical Company, AstraZeneca, Novartis AG, Pfizer, Merck & Company Inc., Rosuvastatin Calcium, Crestor, Pharmaceuticals, Drugs, Atorvastatin Calcium, Lipitor, Valsartan, Diovan, Ezetimibe, Zetia, Epidemiology.

   This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2008, Biotech Business Week via NewsRx.com.

Return to Cardiovascular Business Alert Section